<DOC>
	<DOC>NCT01414166</DOC>
	<brief_summary>The study will evaluate the use of extended release niacin/laropiprant (ERN/LRPT) combination tablets in a primary prevention population currently not taking or eligible for lipid-modifying therapy (LMT); the population will comprise participants with low to moderate risk for coronary heart disease (CHD), low high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C) at or below goal level, and normal or mildly elevated triglyceride (TG) levels.</brief_summary>
	<brief_title>Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108)</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<criteria>Inclusion criteria: LMT ineligible Participants must meet the lipid criteria of "low to moderate CHD risk" as defined by National Cholesterol Education Program Adult Treatment Panel III Framingham Point Scores (NCEP ATP III) HDLC &lt;40 mg/dL (1.03 mmol/L) in males and &lt;50 mg/dL (1.29 mmol/L) in females Triglyceride (TG) level &lt;300 mg/dL (3.39 mmol/L). Fasting serum glucose (FSG) at Visit 1 AND Visit 2 &lt;126 mg/dL (&lt;7 mmol/L) Hemoglobin A1c (HbA1c) level &lt;6.5% Participant willing to use acceptable method of contraception during the study, including the 14day followup period Exclusion criteria: History of malignancy ≤5 years prior to signing informed consent, except for adequatelytreated basal cell or squamous cell skin cancer or in situ cervical cancer Participation in a study with an investigational compound (nonlipidmodifying) within 30 days Pregnant, breastfeeding, or expecting to conceive, or father a child during the study, including the 14day followup period Consumption of more than 3 alcoholic drinks on any given day or more than 14 drinks per week Engages in or plans to engage in vigorous exercise or an aggressive diet regimen during the study Diabetes mellitus, based on medical history, FSG ≥126 mg/dL (7 mmol/L), and HbA1c ≥6.5% Risk factors for coronary heart disease Active or chronic hepatobiliary or hepatic disease Active peptic ulcer disease within 3 months of Visit 1 History of hypersensitivity or allergic reaction to niacin or niacincontaining products Episode of gout within 1 year of Visit 1, unless currently stable on allopurinol Taking an LMT (including statins, bile acid sequestrants, fibrates and niacin &gt;50 mg as monotherapy or coadministered with other LMTs) Use of overthe counter or traditional medicine (e.g. red yeast rice products) for lipidlowering Receiving treatment with systemic corticosteroids (unless on stable therapy for at lest 6 weeks for replacement for pituitary/adrenal/hypogonadal disease) Uncontrolled illness or infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>